Organization (Other)
CSPC Ouyi Pharmaceutical Co., Ltd.
ClinicalTrials.gov lists CSPC Ouyi Pharmaceutical Co., Ltd. as lead sponsor of 29 trials. It has 41 active development programs and 9 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 6 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 7 in 2026 and about 7 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers CSPC Ouyi Pharmaceutical Co., Ltd.: 29 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (42)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 10 |
| Lymphoma | 8 |
| Lymphoma, Non-Hodgkin | 8 |
| Diabetes Mellitus | 4 |
| Lymphoma, T-Cell, Peripheral | 4 |
Showing 5 of 42 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 8 |
| 2024 | 10 |
| 2023 | 9 |
| 2022 | 12 |
| 2021 | 10 |
| 2020 | 4 |
| 2019 | 10 |
| 2018 | 1 |
| 2013 | 1 |
Prediction, not a registry value: median of 23 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 7 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (41)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| GEMCITABINE | Pancreatic Neoplasms | Phase 3 | 1 |
| Dextromethorphan and Bupropion Sustained-Release Tablets | Major Depressive Disorder | Phase 3 | 1 |
| S-1 | Pancreatic Neoplasms | Phase 3 | 1 |
| Liposomal Irinotecan | Pancreatic Neoplasms | Phase 3 | 1 |
| OXALIPLATIN | Pancreatic Neoplasms | Phase 3 | 1 |
Showing 5 of 41 active programs.
Approved assets (9)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| OXALIPLATIN | 2 |
| GEMCITABINE | 2 |
| "Capecitabine" | 1 |
| Pilocarpine HCl Ophthalmic Solution | 1 |
| Calcium Leucovorin | 2 |
Showing 5 of 9 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 20% hit target (n=5) | 80% on time (n=5) |
Journals published in (41)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Lancet. Oncology | 5 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 3 |
| BMC cancer | 3 |
| Cancer | 3 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 3 |
Showing 5 of 41 journals.
Organization relationships (10)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Xiaohui He | Co sponsors trial with | 1 |
| Kuirong Jiang | Co sponsors trial with | 1 |
| The First Hospital of Jilin University | Co sponsors trial with | 1 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Co sponsors trial with | 1 |
| Liling Zhang | Co sponsors trial with | 1 |
Showing 5 of 10 relationships.
Latest dated events (71)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 71 events.
Biomarker capability evidence (250)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 250 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.